Alogliptin (NESINA), a dipeptidyl peptidase IV (DPP-4) inhibitor, was approved by the FDA on January 25, 2013 to improve blood sugar control in adults with type 2 diabetes. This drug had been ...

Get detailed information on Alogliptin, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...

As shown in Figure 2 and 3, the pooled SMDs for alogliptin 12.5 mg treated vs controls, and alogliptin 25 mg treated vs controls demonstrated a significant reduction in HbA1c in patients treated ...

Alogliptin helps stimulate the release of insulin after a meal, which leads to better blood sugar control.” Mary Parks, M.D., director of the Division of Metabolism and Endocrinology Products in ...

If you are already taking both alogliptin and metformin as separate tablets, Nesina Met can replace them in one tablet. Nesina Met is not for patients with type 1 diabetes mellitus or diabetic ...

And for Takeda's alogliptin, a dipeptidyl peptidase 4 inhibitor for type 2 diabetes, the PDUFA date was extended from October 2008 to June 2009. Although big pharma may be able to bear the ...

including the dipeptidyl peptidase 4 inhibitor alogliptin, which has been submitted for regulatory approval to treat diabetes. In 2007, Wilson became President and Chief Scientific Officer of ...

It lowers the amount of liver-produced glucose and makes muscle more insulin-sensitive. Other types of medications called DPP-4 inhibitors—such as alogliptin (Nesina) and sitagliptin (Januvia)—improve ...

Suggested remit: To appraise the clinical and cost effectiveness of insulin icodec within its marketing authorisation for treating type 2 diabetes. Following an update from the company (Novo Nordisk), ...

Get detailed information on Alogliptin and Pioglitazone, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it.